Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $4.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors including Atossa Therapeutics’ strong financial position and promising developments in their endoxifen program. The company reported a solid cash balance, which is expected to provide financial runway until 2027, allowing them to advance their clinical programs without immediate financial pressure.
Additionally, Atossa’s endoxifen has shown potential advantages over the current standard of care, tamoxifen, by reaching therapeutic levels much faster, which is crucial in treating ER+/HER2- metastatic breast cancer. Positive feedback from the FDA regarding their proposed dose-optimization trial further supports the potential for endoxifen to progress towards a registration study. The company’s alignment with FDA’s Project Optimus and previous encouraging clinical data also contribute to the optimistic outlook for Atossa’s stock.
McCarthy covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Brainstorm Cell Therapeutics, and OS Therapies Incorporated. According to TipRanks, McCarthy has an average return of -21.3% and a 26.76% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.